Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of MDX-010 with prophylactic budesonide versus placebo in unresectable stage III/IV melanoma
2005-002678-31Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing Ipilimumab + budesonide with Ipilimumab + placebo (2 arms). Primary endpoints: Rate of grade 2/3/4 diarrhea, Safety and 10 more. Started Apr 2006; status: completed.
02
Drugs
ipilimumabbudesonide
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-002678-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002678-31.